Literature DB >> 20575711

Mammographic breast density and tolerance for short-term postmenopausal hormone therapy suspension.

Erin J Aiello Bowles1, Melissa L Anderson, Susan D Reed, Katherine M Newton, E Dawn Fitzgibbons, Deborah Seger, Diana S M Buist.   

Abstract

BACKGROUND: Breast density tends to decrease when women stop taking hormone therapy (HT). Some women find HT cessation difficult to tolerate, possibly because of fluctuations in endogenous hormone levels and vasomotor symptoms. We hypothesized that women with dense breasts might have lower tolerance for short-term HT suspension than do women with fatty breasts.
METHODS: As part of the Radiologic Evaluation And breast Density (READ) trial, we randomly assigned 881 women aged 45-80 with a prior screening (index) mammogram to suspend HT for 1 or 2 months before their next screening (study) mammogram. We measured continuous breast density on index mammograms using computer-assisted thresholding. At study mammograms, women indicated tolerance for stopping HT from 1 (extremely difficult) to 7 (very easy). Using linear regression, we evaluated the association between index breast density and tolerance after cessation, adjusting for age, body mass index (BMI), HT type, randomization group, and vasomotor symptoms.
RESULTS: A higher percentage of breast density was associated with lower unadjusted mean tolerance scores (tolerance 4.27, 95% confidence interval [CI] 3.77-4.77 for women with > or =50% density, and 4.73, 95% CI 4.45-5.01 for women with <10% density, not a statistically significant difference). In adjusted analyses, neither percent breast density nor dense breast area was associated with tolerance for HT suspension.
CONCLUSIONS: Although HT use affects breast density, tolerance for suspending HT is not associated with breast density. Women with dense breasts have the greatest potential for decreases in density after HT cessation; they should tolerate stopping HT as well as women with fatty breasts.

Entities:  

Mesh:

Year:  2010        PMID: 20575711      PMCID: PMC2941404          DOI: 10.1089/jwh.2009.1681

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  41 in total

1.  Past oral contraceptive and hormone therapy use and endogenous hormone concentrations in postmenopausal women.

Authors:  Mei-Fen Chan; Mitch Dowsett; Elizabeth Folkerd; Nicholas Wareham; Robert Luben; Ailsa Welch; Sheila Bingham; Kay-Tee Khaw
Journal:  Menopause       Date:  2008 Mar-Apr       Impact factor: 2.953

2.  Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.

Authors:  Wulf H Utian; David F Archer; Gloria A Bachmann; Christopher Gallagher; Francine n Grodstein; Julia R Heiman; Victor W Henderson; Howard N Hodis; Richard H Karas; Rogerio A Lobo; JoAnn E Manson; Robert L Reid; Peter J Schmidt; Cynthia A Stuenkel
Journal:  Menopause       Date:  2008 Jul-Aug       Impact factor: 2.953

3.  Effects of a short-term suspension of hormone replacement therapy on mammographic density.

Authors:  N Colacurci; F Fornaro; P De Franciscis; D Mele; M Palermo; W del Vecchio
Journal:  Fertil Steril       Date:  2001-09       Impact factor: 7.329

4.  A study of women on long-term hormone replacement therapy and their attitude to suggested cessation.

Authors:  E Horner; J Fleming; J Studd
Journal:  Climacteric       Date:  2006-12       Impact factor: 3.005

5.  Breast cancer risk and measured mammographic density.

Authors:  M J Yaffe; N F Boyd; J W Byng; R A Jong; E Fishell; G A Lockwood; L E Little; D L Tritchler
Journal:  Eur J Cancer Prev       Date:  1998-02       Impact factor: 2.497

6.  Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study.

Authors:  Linda E Kelemen; V Shane Pankratz; Thomas A Sellers; Kathy R Brandt; Alice Wang; Carol Janney; Zachary S Fredericksen; James R Cerhan; Celine M Vachon
Journal:  Am J Epidemiol       Date:  2008-04-02       Impact factor: 4.897

7.  Associations between mammographic density and body composition in Hispanic and non-Hispanic white women by menopause status.

Authors:  Graciela Caire-Juvera; Leslie A Arendell; Gertraud Maskarinec; Cynthia A Thomson; Zhao Chen
Journal:  Menopause       Date:  2008 Mar-Apr       Impact factor: 2.953

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease.

Authors: 
Journal:  Obstet Gynecol       Date:  2008-11       Impact factor: 7.661

10.  Breast cancer after use of estrogen plus progestin in postmenopausal women.

Authors:  Rowan T Chlebowski; Lewis H Kuller; Ross L Prentice; Marcia L Stefanick; JoAnn E Manson; Margery Gass; Aaron K Aragaki; Judith K Ockene; Dorothy S Lane; Gloria E Sarto; Aleksandar Rajkovic; Robert Schenken; Susan L Hendrix; Peter M Ravdin; Thomas E Rohan; Shagufta Yasmeen; Garnet Anderson
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.